Merck KGaA Earnings Growth Beats Expectations — Update
The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...
bnnbloomberg6h
Merck KGaA Beats Estimates on Boost From Life Science Unit
Its health care business showed good profitability thanks to multiple sclerosis drug Mavenclad and cancer drug Erbitux, as ...
Merck KGaA: A Continued Long-Term Upside Despite Some Lag
Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...
Investing28d
Merck KGaA shares jump as FY24 outlook reaffirmed
Investing.com -- Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales projections, particularly for its Life Science and ...